Table 5 Associations of cluster A, B, C and D to clinical characteristics.
All n = 187(%) | Cluster A n = 35 (%) | Cluster B n = 46 (%) | Cluster C n = 53(%) | Cluster D n = 53(%) | P1 | |
|---|---|---|---|---|---|---|
Age | 180 | 0.014 | ||||
< 50 years | 47 (26) | 3(9) | 9(20) | 15(30) | 20(38) | |
≥50 years | 133 (74) | 30(91) | 36(80) | 35(70) | 32(62) | |
Tumor size | 167 | 0.601 | ||||
≤20 mm | 46 (28) | 11(33) | 13(30) | 13(28) | 9(20) | |
> 20 mm | 121 (72) | 22(67) | 30(70) | 34(72) | 35(80) | |
Lymph node status | 166 | 0.161 | ||||
Negative (n = 0) | 52 (31) | 8(24) | 10(23) | 15(32) | 19(44) | |
Positive (n > 0) | 114 (69) | 25(76) | 33(77) | 32(68) | 24(56) | |
S-phase fraction | 119 | 0.001 | ||||
Low (< 12%) | 75 (63) | 19(79) | 25(86) | 12(43) | 19(50) | |
High (≥12%) | 44 (37) | 5(21) | 4(14) | 16(57) | 19(50) | |
ER | 180 | 0.009 | ||||
Negative (< 25 fmol/mg) | 86 (48) | 12(34) | 15(33) | 32(62) | 27(56) | |
Positive (≥25 fmol/mg) | 94 (52) | 23(66) | 30(67) | 20(38) | 21(44) | |
PgR | 178 | 0.023 | ||||
Negative (< 25 fmol/mg) | 107 (60) | 16(48) | 20(47) | 38(73) | 33(66) | |
Positive (≥25 fmol/mg) | 71 (40) | 17(52) | 23(53) | 14(27) | 17(34) | |
HER2 | 82 | 0.012 | ||||
Weak/negative | 63 (77) | 8(62) | 24(92) | 15(60) | 16(89) | |
Strong (score = 3) | 19 (23) | 5(38) | 2(8) | 10(40) | 2(11) | |
EGFR | 69 | 0.188 | ||||
Weak/negative | 58 (84) | 10(100) | 15(79) | 20(91) | 13(72) | |
Strong (score≥7) | 11 (16) | 0(0) | 4(21) | 2(9) | 5(28) | |
PTEN | 110 | 0.511 | ||||
Negative | 34 (31) | 5(26) | 7(23) | 12(40) | 10(33) | |
Positive | 76 (69) | 14(74) | 24(77) | 18(60) | 20(67) | |
PIK3CA | 107 | 0.015 | ||||
Wildtype | 76 (71) | 10(56) | 16(55) | 26(87) | 24(80) | |
Mutation | 31 (29) | 8(44) | 13(45) | 4(13) | 6(20) | |
Distant metastasis | 149 | 0.269 | ||||
Negative | 99 (66) | 22(67) | 32(78) | 23(59) | 22(61) | |
Positive | 50 (33) | 11(33) | 9(22) | 16(51) | 14(39) |